SIBO small intestine bacterial growth syndrome

SIBO (*Small Intestinal Bacterial Overgrowth*) represents a pathological condition characterized by the colonization of the small intestine by aberrant bacterial strains or by the excessive proliferation of indigenous microbial populations (exceeding 10⁵ colony-forming units—CFU—per milliliter of intestinal content). This disruption of microbial equilibrium may precipitate a spectrum of gastrointestinal symptoms alongside systemic complications.

Epidemiological evidence suggests that this disorder may affect as much as one-fifth of the adult population, with prevalence rates reaching up to 22%. The aberrant colonization of the small intestine by pathogenic microorganisms gives rise to a spectrum of debilitating gastrointestinal symptoms, including abdominal pain syndromes, recurrent episodes of nausea and vomiting, excessive intestinal gas accumulation, chronic disturbances in bowel habits (manifesting as either constipation or diarrhea), postprandial fullness, gastroesophageal reflux, gastric mucosal inflammation, anemia, and food hypersensitivity reactions. Furthermore, this dysbiosis may present with extraintestinal manifestations such as depressive mood disorders, persistent fatigue, arthralgias or myalgias, and cutaneous abnormalities. The underlying pathophysiological mechanism involves the fermentation of undigested food particles by the aberrant microbial flora, resulting in excessive gas production—a process that, while physiologically normal in the large intestine, becomes highly symptomatic when occurring in the small intestine. Additionally, hydrogen-producing bacteria create a favorable environment for methanogenic archaea, thereby dictating the predominant clinical presentation: archaea dominance (methane producers) correlates with constipation, whereas hydrogen-producing bacterial dominance aligns with diarrhea. Alternating constipation and diarrhea may indicate concurrent colonization by both microbial types or a coexisting fungal infection.

The equilibrium of intestinal microbiota within the gastrointestinal tract is governed by a multifaceted interplay of mechanical, biochemical, and immunological factors. Key regulatory components include: optimal gastric acidity, pancreatic enzyme activity, the presence of bile salts, and coordinated intestinal motility. Dysfunction in any of these systems may precipitate aberrant bacterial proliferation in the proximal segments of the small intestine, where microbial populations are normally sparse under physiological conditions. In the pathogenesis of **Small Intestinal Bacterial Overgrowth (SIBO)**, several critical abnormalities are implicated: **achlorhydria** (absence or severe reduction of hydrochloric acid secretion, e.g., due to prolonged proton pump inhibitor therapy), **enzymatic deficiencies** (particularly in exocrine pancreatic insufficiency, as seen in cystic fibrosis), **immune dysfunctions** (e.g., selective IgA deficiency, HIV/AIDS, common variable immunodeficiency), and **structural or functional gastrointestinal anomalies** (including strictures, small bowel tumors, diverticula, post-surgical states). SIBO frequently coexists with celiac disease, Crohn’s disease, short bowel syndrome, non-alcoholic fatty liver disease, cirrhosis, and diabetic neuropathy. Additional contributing factors include: **increased intestinal barrier permeability** („*leaky gut syndrome*“), **ileocecal valve incompetence** (permitting retrograde bacterial translocation), and **disruptions in the *migrating myoelectric complex* (MMC)**—a cyclic motor activity essential for clearing the small intestine of residual nutrients and microorganisms. When these regulatory mechanisms fail, colonization by bacteria such as *Bacteroides*, *Lactobacillus*, *Clostridium*, *Streptococcus*, *Escherichia coli*, *Staphylococcus*, *Klebsiella pneumoniae*, *Enterococcus spp.*, and *Proteus mirabilis* occurs, with their metabolic byproducts (e.g., hydrogen, methane) driving clinical symptomatology.

The diagnosis of **small intestinal bacterial overgrowth (SIBO)** presents significant clinical challenges, primarily due to the **non-specific and heterogeneous symptom presentation** as well as **limited awareness and diagnostic infrastructure** among healthcare providers in Poland. Currently, the **only available diagnostic method** in the country is the **hydrogen breath test (HBT)**, which quantifies hydrogen concentrations—a bacterial metabolic byproduct—in exhaled air. In regions with more advanced diagnostic capabilities, the **methane breath test** is also utilized, though it remains **unavailable in Poland at present**. The HBT is conducted using a **gastrolyzer**, a device functionally analogous to a breathalyzer. The patient ingests a solution containing **lactulose or glucose**, followed by **serial measurements every 20 minutes over a 3-hour period**. The **baseline measurement** is taken **prior to solution consumption**. In healthy individuals, fasting hydrogen levels should not exceed **10 parts per million (ppm)**, with post-ingestion values remaining below **20 ppm**. A diagnosis of SIBO is confirmed if **any measurement between 90 and 120 minutes** demonstrates a **≥20 ppm increase** relative to baseline. Since humans lack enzymes capable of digesting lactulose (a process exclusively performed by colonic bacteria in healthy individuals), the test can identify the **moment lactulose exits the small intestine**, marked by a **sharp rise in hydrogen levels** (the *„second peak“*). This second peak is physiological in healthy subjects, whereas an **early peak** suggests pathology. Interpretation of the **time-concentration curve** enables diagnosis. **Critical preparatory steps** include: **12-hour fasting** (only plain water permitted), abstinence from alcohol, tobacco, and chewing gum, and adherence to a **low-residue diet** the prior day (excluding fatty, fried, gas-producing, or high-fructose/lactose foods). Patients must also **discontinue vitamin/mineral supplements and laxatives 24 hours beforehand** and perform **oral hygiene immediately before testing**. **Relative contraindications** include recent antibiotic therapy, colonoscopy, and reactive hypoglycemia.

The management of small intestinal bacterial overgrowth (SIBO) presents a formidable challenge for both patients and healthcare providers, given the divergent expert opinions regarding the most effective strategies for mitigating excessive bacterial colonization in the small intestine. Conventional therapeutic protocols primarily rely on antibiotic pharmacotherapy, with metronidazole, doxycycline, and rifaximin—an antibiotic characterized by its selective activity against enteric bacteria—being the most frequently prescribed agents. Upon completion of antibiotic treatment, the implementation of targeted probiotic and prebiotic supplementation is essential to restore the compromised colonic microbiota. The selection of probiotics should be individualized, prioritizing formulations that incorporate a diverse array of bacterial strains, while also advocating for the rotational use of probiotic preparations with distinct microbial compositions. An equally critical component of therapy involves the correction of nutritional deficiencies, achievable through both dietary modifications and the strategic supplementation of essential micronutrients. Complementary and alternative approaches leverage bioactive phytochemicals derived from plants such as wormwood (*Artemisia absinthium*), cat’s claw (*Uncaria tomentosa*), pau d’arco (*Tabebuia impetiginosa*), garlic, oregano oil, and lauric acid found in coconut oil—preferably in the form of standardized extracts with documented antimicrobial efficacy. From a dietary perspective, specialized nutritional regimens have demonstrated utility, including the low-FODMAP diet, the specific carbohydrate diet (SCD), and the therapeutic protocol developed by Dr. Allison Siebecker. It is important to acknowledge, however, that SIBO treatment is a protracted process demanding persistence and patience, with complete symptom remission not always attainable. Nonetheless, a comprehensive approach integrating pharmacological interventions, dietary adjustments, and precision probiotic therapy has the potential to substantially enhance patients’ quality of life.